참고문헌
- Akaza H, Hinotsu S, Usami M, et al (2009). Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer, 115, 3437-45. https://doi.org/10.1002/cncr.24395
- Cookson MS, Roth BJ, Dahm P, et al (2013). Guidelines for the castration-resistant prostate cancer: American Urological Association. J Urol, 190, 429-38. https://doi.org/10.1016/j.juro.2013.05.005
- Choi JI, Kim YB, Yang SO, et al (2011). Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade. Korean J Urol, 52, 461-5. https://doi.org/10.4111/kju.2011.52.7.461
- Desai A, Stadler WM, Vogelzang NJ (2001). Nilutamide:possible utility as a second-line hormonal agent. Urology, 58, 1016-20. https://doi.org/10.1016/S0090-4295(01)01455-8
- European Association of Urology (2013). Guidelines on prostate cancer: European Association of Urology.
- Joyce R, Fenton MA, Rode P, et al (1998). High dose bicalutamide for androgen independent prostate cancer:effect of prior hormonal therapy. J Urol, 159, 149-53. https://doi.org/10.1016/S0022-5347(01)64039-4
- Kojima S, Suzuki H, Akakura K, et al (2004). Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol, 171, 679-83. https://doi.org/10.1097/01.ju.0000106190.32540.6c
- Labrie F (2010). Hormonal therapy of prostate cancer. Prog Brain Res, 182, 321-41. https://doi.org/10.1016/S0079-6123(10)82014-X
- Lam JS, Leppert JT, Vemulapalli SN, et al (2006). Secondary hormonal therapy for advanced prostate cancer. J Urol, 175, 27-34. https://doi.org/10.1016/S0022-5347(05)00034-0
- Maffezzini M, Bossi A, Collette L (2007). Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol, 51, 605-13. https://doi.org/10.1016/j.eururo.2006.10.062
- Mazumdar M, Glassman JR (2000). Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med, 19, 113-32. https://doi.org/10.1002/(SICI)1097-0258(20000115)19:1<113::AID-SIM245>3.0.CO;2-O
- McGrowder DA, Jackson LA, Crawford TV (2012). Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev, 13, 1-13. https://doi.org/10.7314/APJCP.2012.13.1.001
- Miyake H, Hara I, Eto H (2005). Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int, 96, 791-5. https://doi.org/10.1111/j.1464-410X.2005.05766.x
- National Comprehensive Cancer Network (2014) Clinical practice guidelines in oncology: prostate cancer. version 1.2014.
- Nishimura K, Arichi N, Tokugawa S, et al (2007). Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. Int J Urol, 14, 264-7. https://doi.org/10.1111/j.1442-2042.2007.01681.x
- Okegawa T, Nutahara K, Higashihara E (2010). Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience. Int J Urol, 17, 950-5. https://doi.org/10.1111/j.1442-2042.2010.02620.x
- Okihara K, Ukimura O, Kanemitsu N, et al (2007). Kyoto Prefectural University of Medicine Prostate Cancer Research Group. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Int J Urol, 14, 128-32. https://doi.org/10.1111/j.1442-2042.2007.01698.x
- Prostate Cancer Trialists’ Collaborative Group (2000). Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet, 355, 1491-8. https://doi.org/10.1016/S0140-6736(00)02163-2
- Scher HI, Liebertz C, Kelly WK, et al (1997). Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol, 15, 2928-38.
- Situmorang GR, Umbas R, Mochtar CA, et al (2012). Prostate cancer in younger and older patients: do we treat them differently? Asian Pac J Cancer Prev, 13, 4577-80. https://doi.org/10.7314/APJCP.2012.13.9.4577
- Suzuki H, Okihara K, Miyake H, et al (2008). Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol, 180, 921-7. https://doi.org/10.1016/j.juro.2008.05.045